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Abstract
 This goal of this research was to evaluate the cost-effectiveness of the National Cancer Screening 
Program (NCSP) for breast cancer in the Republic of Korea from a government expenditure perspective. In 
2002-2003 (baseline), a total of 8,724,860 women aged 40 years or over were invited to attend breast cancer 
screening by the NCSP. Those who attended were identified using the NCSP database, and women were 
divided into two groups, women who attended screening at baseline (screened group) and those who did not 
(non-screened group). Breast cancer diagnosis in both groups at baseline, and during 5-year follow-up was 
identified using the Korean Central Cancer Registry. The effectiveness of the NCSP for breast cancer was 
estimated by comparing 5-year survival and life years saved (LYS) between the screened and the unscreened 
groups, measured using mortality data from the Korean National Health Insurance Corporation and the 
National Health Statistical Office. Direct screening costs, indirect screening costs, and productivity costs were 
considered in different combinations in the model. When all three of these costs were considered together, 
the incremental cost to save one life year of a breast cancer patient was 42,305,000 Korean Won (KW) 
(1 USD=1,088 KW) for the screened group compared to the non-screened group. In sensitivity analyses, 
reducing the false-positive rate of the screening program by half was the most cost-effective (incremental 
cost-effectiveness ratio, ICER=30,110,852 KW/LYS) strategy. When the upper age limit for screening was 
set at 70 years, it became more cost-effective (ICER=39,641,823 KW/LYS) than when no upper age limit 
was set. The NCSP for breast cancer in Korea seems to be accepted as cost-effective as ICER estimates were 
around the Gross Domestic Product. However, cost-effectiveness could be further improved by increasing 
the sensitivity of breast cancer screening and by setting appropriate age limits.
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Introduction
 Breast cancer has become a leading cancer among 
women in the Republic of Korea, with an annual percent 
change of 6.6% in the incidence rate between 1999 and 
2007 (Oh et al., 2011), and an annual increase in mortality 
of 4.3% from 1983-1993, and 2.4% from 1994-2007 
(Jung et al., 2010). The incidence rate of breast cancer 
among women in Korea is markedly lower than that in the 
West (incidence rate is 1/4-1/8 that in the United States) 
(Park et al., 2009). Moreover, the highest incidence of 
breast cancer occurs among Korea women in their 40s, 
and decreases after age 50 (Park et al., 2009), whereas 
breast cancer incidence in the United States continues 
to increase with age. The National Cancer Screening 
Program (NCSP) in Korea recommends biennial breast 
cancer screening by mammography for women aged 40 
years or older (Ministry of Helalth and Welfare, 2002). 
In the United States and Canada, women aged 50-74 
years are recommended to receive a mammography 
every 2-3 years (U.S. Preventive Service Task Force, 
2009; Canadian Task Force on Preventive Health Care, 
2011). In the United Kingdom, the National Health 
Service recommends that women aged 50-70 years 
receive a mammography every 3 years (National Cancer 
Screening Committe, 2010), and Japanese women are 
recommended to receive a mammography as from age 
40 every 1-2 years (National Cancer Center, 2009).
 In 1996, the Korean government established the 
comprehensive ‘10-year Plan for Cancer Control’. The 
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NCSP, which is administered by the Ministry of Health 
and Welfare, was established in 1999 as part of this plan 
to provide screening for gastric, breast, and cervical 
cancer free of charge to Medical Aid Program recipients 
(Jung et al., 2010; Lee et al., 2011; Han et al., 2012; 
Park et al., 2012b). Since then, free screening services 
were expanded and in 2002-2003, all National Health 
Insurance beneficiaries could use the screening services 
of the NCSP (Lee et al., 2011; Park et al., 2011; 2012a). 
 The reported breast cancer screening rate in Korea 
increased from 55.9% in 2004 to 79.5% in 2010 (Ministry 
of Helalth and Welfare and National Cancer Center, 
2011). However the high number of false-positive 
screening results has kept the sensitivity of breast cancer 
screening very low, and therefore the cost-effectiveness 
of the NCSP for breast cancer remains unclear. Thus, 
we investigated the cost-effectiveness of the NSCP for 
breast cancer. Costs considered included direct, indirect 
and productivity costs related to breast cancer screening, 
and effectiveness outcomes included 5-year survival and 
life years saved (LYS).
Materials and Methods
Study population and data sources
 The study population comprised women invited to 
attend breast cancer screening between 1 January 2002 
and 31 December 2003 (baseline) by the NCSP for breast 
cancer, which targets all women aged 40 years or over. 
As Korean women are to undergo screening at even-
numbered ages (i.e., 40, 42, etc.), the 2-year baseline 
screening period used in the present study should include 
all women in the target screening population. Women 
who attended breast cancer screening were identified 
using the NCSP database, and divided into two groups: 
women who attended screening at baseline (screened 
group) and those who did not (non-screened group). 
Breast cancer diagnosis in both groups at baseline, and 
during 5-year follow-up was identified using the Korean 
Central Cancer Registry (KCCR). Breast cancer mortality 
data was collected from the Korean National Health 
Insurance Corporation and the National Statistical Office. 
Cost data were obtained from the internal accounts of 
screening units, published studies, and national statistics.
Screening results
 Screening results recorded as ‘breast cancer doubt’ 
or ‘breast cancer’, were regarded as positive. The false-
positive rate was calculated as the portion of breast 
cancers recorded in the KCCR, minus true-positive 
screening results, divided by the total number of positive 
screening results.
Cost-effectiveness model
 To determine cost-effectiveness, costs and 
effectiveness outcomes were compared between 
the screened and non-screened groups. Actual cost 
values were used in all cost-effectiveness analyses; no 
hypothetical or derived cost values were employed. Both 
outcomes and costs were age-adjusted for the standard 
population of National Statistics Korea. 
Costs
 Three cost combinations were considered in the 
cost-effectiveness analysis model. COST Ⅰ included 
direct screening costs, i.e., screening costs and additional 
costs for further testing after false-positive screening 
results. Screening costs consisted of full-picture 
archiving communication system examination, film, 
and consultation fee. Additional costs for further testing 
after false-positive screening results included cost of 
ultrasound, biopsy, 20% of the mammotome costs, 
since it was assumed that mammotome examination 
was conducted in a selective manner, and consultation 
fee (Table 1).
 COST Ⅱ included direct and indirect screening costs, 
i.e., costs in COST I plus transportation costs (two-way). 
The same transportation costs were also added to the 
additional costs for further testing after false-positive 
screening results. COST I and COST II applied to 
the screened group only, and did not include the non-
screened group.
 COST Ⅲ considered all costs in COST II plus 
productivity costs, defined as loss of salary due to 
screening participation. To determine productivity cost, 
annual average salary was used to calculate a daily 
wage in each age group. This was then multiplied by the 
average economic activity rate in each age group. For 
housewives, daily wages for housework were multiplied 
by a woman’s non-economic activity rate. We assumed 
productivity costs corresponding to about half of an 
average day for women to participate in breast cancer 
screening (Table 1). All costs were inflated to values 
for the year 2009 using consumer indexes. For the base 
cost-effectiveness analysis, COST Ⅲ was utilized.
Effectiveness
 Five-year survival and LYS were used as effectiveness 
outcomes, and were compared between the screened and 
the unscreened groups. LYS was calculated for different 
survival scenarios as follows: it was considered that 
women who survived the 5-year follow-up period lived 
until their last year of life-expectancy. LYS for women, 
who died within 5 years of their cancer diagnosis, was 
calculated as the number of years between date of 
diagnosis and death. The same method was applied to the 
screened and non-screened groups. Both 5-year survival 
and LYS are presented per 100,000 women in each group 
for the same of comparability. 
Sensitivity analyses
 Uncertainty in cost-effectiveness analyses was 
examined by sensitivity analyses, in which four factors 
that were expected to have an effect on the result were 
varied: mammotome utilization, rate of false-positive 
screening results, productivity cost, and upper age limits 
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for breast cancer screening. 
 Separate analyses were run supposing that: 1) 
mammotome utilization increased from 20% to 40%, 
2) mammotome utilization increased to 50%, 3) false-
positive screening results were decreased to half (false-
positive rate: 8.77% rather than 17.54), or 4) false-
positive screening results increased two-fold (35.07%), 
and 5) the average productivity costs increased by 10%. 
We also conducted a sensitivity analysis using upper age 




Screening participation and cancer detection
 A total of 8,724,860 women aged 40 years or over 
were invited to attend breast cancer screening by the 
NCSP at baseline. Among them, 993,108 (11.38%) 
participated in screening at baseline (Table 2). Women 
in their 50s showed the highest participation rate (over 
14%), but after the age of 70 years, the participation rate 
fell below 10%.
 Of those screened, 17.59% were referred to further 
testing due to positive screening results (‘breast cancer 
diagnosis’ or ‘breast cancer doubt’) (Table 2). Among 
screening participants in their 40s, about 25% had a 
positive screening result. The rate of positive screening 
results decreased with age in our study population. In the 
screening group, 635 women had a confirmed diagnosis 
of breast cancer, rendering a rate of true-positive results 
of 0.36% at baseline (Table 2). 
 The numbers of breast cancer cases identified during 
5-year follow-up are reported in Table 3 for both the 
screened and non-screened groups. More women in the 
screened group were found to have breast cancer than 
in the non-screened group, but breast cancer incidence 
increased during 5-year follow-up for both groups (Table 
3). In the first year of follow-up, 151 cases of breast 
Table 1. Costs for the Screened Group Used in the Analysis of the National Cancer Screening Program
Cost type Amount (KW)
Direct screening cost 
 (1) Cost of screening test 
  Full PACS & films (24,960 KWa) + Consultation (5,120 KWb) 30,080
 (2) Costs of further testing due to false-positive screening result 
  Ultrasound/biopsy (262,000 KWb) + Mammotome 20%c (20%*1,150,000 KWb) + Consultation (16,880 KWb) +  511,704
  specialty consultation fee 50% (50%*5,648 KWb,d) 
Indirect screening cost 
 Transportation (one-way): 11,702e 
 Two-way travel cost: 11,702*2 23,404
Productivity cost 
 Attendee’s average productivity costs for half day 
 Equation: {(average daily wage * economic activity rate) + (wages for housework * non-economic activity rate)} * 1/2
  Age 40-49 y: {80,911 KW*0.644 + 52,175 KW*1-0.644)}*1/2 35,341f
  Age 50-59 y: {74,054 KW*0.541 + 47,017 KW*(1-0.541)}*1/2 30,827f
  Age over 60 y: {60,811 KW*0.286 + 47,017 KW*(1-0.286)}*1/2 25,478f
*All unit costs were inflated to 2009 values; aSource: National Cancer Screening Program guidebook. 2002-2011. Division of Cancer Policy, Ministry of Health and 
Welfare; bSource: Data obtained from the Division of Medical Information and Technology, Yonsei University Health System, Seoul; cThe cost for mammotome 
was multiplied by 20% as it was assumed that about 20% of patients with false-positive screening results received retesting with mammotome. dThe cost for 
specialty consultation fee was multiplied by 50% for this analysis under the assumption that half of the participants with false-positive screening results received 
specialty consultation and the remaining half received retesting from a general physician. eSource: The Third Korea National Health and Nutrition Examination 
Survey (KNHANES Ⅲ), 2005. fSource: Statistics Korea, 2009-2011. Ministry of Employment and Labor, Employment Policy Office. Abbreviations: PACS, picture 
archiving communication system; y, years; KW, Korean Won
Table 2. Participation and Positive Screening Results, National Cancer Screening Program (NCSP) for 
Breast Cancer in 2002-2003    
Age (years) Population invited by NCSP  Participation  Positive screening  True-positive
 for breast cancer   results  screening results
 in 2002 and 2003 N (%) N (%) N (%a)
40-44 2,186,213 242390 (11.1) 62,052 (25.6) 150 (0.2)
45-49 1,317,143 169427 (12.9) 42,018 (24.8) 145 (0.3)
50-54 1,306,525 190121 (14.6) 37,834 (19.9) 119 (0.3)
55-59 751,456 111905 (14.9) 16,338 (14.6) 87 (0.5)
60-64 1,112,009 145825 (13.1) 17,791 (12.2) 78 (0.4)
65-69 655,993 68891 (10.5) 6,682 (9.7) 27 (0.4)
70-74 677,264 46853 (6.9) 3,233 (6.9) 20 (0.6)
75-79 313,258 12,139 (3.9) 643 (5.3) 7 (1.1)
≥80 404,999 5,557 (1.4) 295 (5.3) 2 (0.7)
Total 8,724,860 993,108 (11.4) 174,787 (17.6) 635 (0.4)
aThe true-positive rate was estimated by the number of breast cancer cases diagnosed divided by the number of positive results from the screening
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cancer were identified in the screened group, compared 
to 94 in the non-screened group (Table 3). The difference 
in cumulative incidence narrowed throughout follow-
up, and by the 5th year, the age-adjusted breast cancer 
incidence rates were 0.46% and 0.45% for the screened 
and non-screened groups respectively (Table 3). 
 On the other hand, the proportion of early-stage 
breast cancers diagnosed in 2002-2003 was larger in the 
screened group (40.0%) than the non-screened group 
(23.4%) (Table 4).
Cost-effectiveness analysis
 Overall mortality due to breast cancer during 5-year 
follow-up was 1.77 times higher in the non-screened 
group than the screened group (39 vs. 22 per 100,000 
women) (Table 4). Women in their 50s showed the 
highest mortality compared to other age groups in both 
the screened and non-screened groups. The incremental 
age-adjusted LYS for the screened group was 402 years, 
increasing by 1.41% compared to the non-screened group 
(Table 4). 
 COST I for breast cancer detection in the NCSP was 
12,031,751 Korean Won (KW) (11,100 US Dollars, USD; 
exchange rate November 2012 1 USD=1,088 KW) (Table 
5). Adding transportation cost to this (COST II) raised 
the cost to 13,345,966 KW (12,300 USD). COST III also 
considered the productivity costs related to screening 
participation, and was 16,987,188 KW (15,600 USD), 
which was about 1.4 times higher than COST Ⅰ (Table 
5). 
 To reduce the number of breast cancer mortalities 
over the 5-year follow-up by one, costs of between 
707,453,000 KW and 998,827,000 KW (650,000 USD-
918,000 USD) were required (Table 5) for the screened 
group compared to the non-screened group (Table 5). 
That is, to save one breast cancer patient among 100,000 
women aged 40 years or over for 5 years, costs related 
to breast cancer screening was about 918,000 USD in 
South Korea. Regarding 5-year survival, women in their 
60’s showed the highest cost-effectiveness (incremental 
cost-effectiveness ratio, ICER=844 million KW) in 
comparison with other age groups (Table 5). The ICER 
of 5-year survival with regard to COST Ⅲ was about 1.4 
times higher than the ICER with Cost Ⅰ.
 To increase LYS by one, the add cost (COST III) was 
as much as 42,305,000 KW (39,000 USD). The ICERs 
were similar across age groups (ICER: 32,532,000 KW-
46,241,000 KW/LYS) except for the age group over 70 
years, which showed an ICER of 109,077,000 KW, more 
than two-fold that of the other age groups (Table 5). The 
Table 3. Cumulative Number of Breast Cancer Detection during 5-year Follow-up between Screened and 
Non-screened Groups (per 100,000 women)
Age 1st year 2nd year 3rd year 4th year 5th year
(years) Screened    Non-Screened Screened    Non-Screened Screened    Non-Screened  Screened    Non-Screened  Screened  Non-Screened
 N    (%)        N    (%) N     (%)         N     (%) N    (%)         N    (%) N     (%)        N     (%) N    (%)         N    (%)
40-44 189 (0.2) 99 (0.1) 292 (0.3) 204 (0.2) 420 (0.4) 312 (0.3) 554 (0.6) 426 (0.4) 646 (0.7) 535 (0.5)
45-49 215 (0.2) 136 (0.1) 329 (0.3) 274 (0.3) 459 (0.5) 414 (0.4) 583 (0.6) 543 (0.5) 661 (0.7) 655 (0.7)
50-54 175 (0.2) 128 (0.1) 281 (0.3) 250 (0.3) 368 (0.4) 358 (0.4) 464 (0.5) 456 (0.5) 528 (0.5) 550 (0.6)
55-59 155 (0.2) 112 (0.1) 235 (0.2) 217 (0.2) 322 (0.3) 313 (0.3) 409 (0.4) 410 (0.4) 474 (0.5) 494 (0.5)
60-64 123 (0.1) 78 (0.1) 189 (0.2) 150 (0.2) 252 (0.3) 226 (0.2) 325 (0.3) 292 (0.3) 364 (0.4) 357 (0.4)
65-69 94 (0.1) 54 (0.1) 126 (0.1) 106 (0.1) 160 (0.2) 156 (0.2) 193 (0.2) 205 (0.2) 222 (0.2) 254 (0.3)
70-74 70 (0.1) 40 (0.04) 107 (0.1) 78 (0.1) 141 (0.1) 110 (0.1) 177 (0.2) 142 (0.1) 203 (0.2) 174 (0.2)
75-79 74 (0.1) 29 (0.03) 99 (0.1) 52 (0.1) 115 (0.1) 79 (0.1) 132 (0.1) 98 (0.1) 132 (0.1) 117 (0.1)
≥80 18 (0.02) 14 (0.01) 18 (0.02) 37 (0.04) 18 (0.02) 49 (0.1) 36 (0.04) 63 (0.1) 36 (0.04) 75 (0.1)
Total 151 (0.2) 94 (0.09) 230 (0.2) 187 (0.2) 315 (0.3) 277 (0.3) 404 (0.4) 364 (0.4) 461 (0.5) 445 (0.5)
*The total frequency values were age-adjusted
Table 4. The Proportion of Early-stage Breast Cancer Detected in 2002-2003, 5-year Mortality and Life-
Years Saved (LYS) among the Screened and Non-screened Groups (per 100,000 women)     
Age (years)              Early-stage cancera                                 5-year mortalityb  LYS differenceb
 Screened Non-screened Screened Non-screened Screened - non-screened (%)
40-44 40.20% 25.40% 17 (0.02%) 28 (0.03%) 427 (1.04%)
45-49 39.30% 26.70% 26 (0.03%) 42 (0.04%) 525 (1.46%)
50-54 38.80% 23.00% 24 (0.02%) 45 (0.05%) 619 (1.94%)
55-59 36.30% 24.60% 31 (0.03%) 49 (0.05%) 414 (1.53%)
60-64 39.10% 23.20% 24 (0.02%) 42 (0.04%) 338 (1.47%)
65-69 33.80% 19.90% 13 (0.01%) 38 (0.04%) 375 (2.08%)
70-74 46.50% 21.40% 32 (0.03%) 33 (0.03%) 11 (0.08%)
75-79 58.30% 17.60% 8 (0.01%) 41 (0.04%) 254 (2.31%)
≥80 50.00% 15.90% 18 (0.02%) 38 (0.04%) 48 (0.60%)
Totalc 40.00% 23.40% 22 (0.02%) 39 (0.04%) 402 (1.41%)
a% of early stage represents the proportion of in-situ and local stages over all breast cancer cases identified during the baseline years of 2002-2003; bOutcomes were 
observed for 5 years after baseline (2002-2003); cTotal values were age-adjusted; LYS, life-years saved
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age group 50-59 showed the lowest incremental costs 
per LYS, which was about 23% lower than the average 
(Table 5). 
Sensitivity analyses 
 The results of sensitivity analyses in terms of ICERs 
regarding LYS during 5-year follow-up are shown in the 
Figure 1. Varying the rate of mammotome examination 
and false-positive screening results, produced different 
ICERs than the base model. When we assumed a 
false-positive rate that was two-fold the current one 
for mammography, the ICER (66.7 million KW/LYS) 
increased about by 36.6% compared to the ICER of the 
base model (Figure 1). As expected, the assumption 
of a lower false-positive rate lowered the ICER over 
the LYS (30.1 million KW/LYS) by 28.8% compared 
to the non-screened group. When the utilization of 
mammotome examination increased to two-fold and 
2.5-fold respectively, the costs per LYS increased to 
52.4 million KW (23.9%) and 61.3 million KW (44.9%), 
respectively (Figure 1). 
 When the ICER values were compared across age 
groups, 50-59 years was the most cost-effective age 
group in the base model, as well as in other sensitivity 
models. On the other hand, the age group over 70 years 
was the least cost-effective for NCSP for breast cancer 
in all sensitivity analyses (Figure 1). 
 When we considered upper age limit from 60 to no 
limit, as in the current program, the ICER ranged between 
39.6 million KW and 42.3 million KW. Indeed, the NCSP 
for breast cancer showed the most cost-effectiveness 
when the upper age limit was set to age 70 years, with 
an ICER of 39.6 million KW/LYS, 0.9 times lower than 
the ICER of the current screening program .
Discussion
In this study, we used the databases of the NCSP and 
the KCCR to determine the incidence and outcomes of 
the NCSP for breast cancer. The ICER in Korean women 
aged 40 years or older, the target population of the NCSP 
for breast cancer, was found to be 42 million KW (USD 
39,000) per LYS, which was a bit higher than the Gross 
Domestic Product (GDP) per capita in South Korea, 
which was approximately 27,168 USD in 2009 (The 
World Bank). However, in most developed countries 
where breast cancer screening programs exist, ICER 
estimates have been reported to be below the national 
GDP per capita. For example, the ICER of organized 
breast cancer screening in Switzerland, taking into 
account mammography and treatment costs, was 14,452 
USD per LYS, which was 26% of the Swiss GDP per 
capita (de Gelder et al., 2009). In Norway and Finland, 
the screening and treatment costs per LYS of women were 
reported to be 10,747 USD and 18,955 USD respectively. 
In the United States, the additional cost to screen women 
aged 50-69 years was 37,000 USD per LYS, representing 
about 87% of their GDP per capita (Wong et al., 2010). 
In Japan, when consultation, treatment and terminal care 
cost were considered, the cost per LYS was 14,300 USD 
for mammography screening, which was 84% of the GDP 
per capita (Okubo et al., 1991). In contrast, the ICER 
estimates for screening Chinese women aged 40-69 years 
with mammogram, including productivity and treatment 
cost (ICER=64,400 USD/LYS) was 37 times higher than 
the GDP per capita (Wong et al., 2007).
The costs for an organized screening program are 
affected by participation rates, cancer detection rates 
and false-positive rates. The participation rate for breast 
cancer screening increased from 14.1% in 2002 to 34.9 % 
in 2008 in Korea (Oh et al., 2010), and the breast cancer 
incidence rate has also recently increased in Korea (Lee 
et al., 2009). As the participation and incidence rates of 
breast cancer in Korea continue to increase, so will the 
ICER of breast cancer screening. 
Among the positive screening results, 635 actual 
cases of breast cancer were detected by the NCSP in 
2002-2003, indicating a 0.36% true-positive rate and a 
high false-positive rate for these years. In Europe, false-
positive mammography results are likely less common 
(Salz et al., 2011). False-positive screening results 
can negatively affect subsequent screening behavior, 
by deterring women from participating in screening, 
which could be a serious public health problem (Oh et 
al., 2011). Also, it has been reported that women who 
Table 5. Incremental Cost-effectiveness Ratios 
(ICER) between the Screened and Non-screened 
Groups (per 100,000 women)
Age Cost  5-year ICERa  LYS ICERb
group (1,000 KW)  survival
All Cost I: 12,031,751 17 707,453 402 29,964
All Cost II: 13,345,966 17 784,727 402 33,237
All Cost III: 16,987,188 17 998,827 402 42,305
40-49  21,944,480 13 1,597,890 474 46,241
50-59  17,160,337 20 844,274 527 32,532
60-69  12,644,006 21 592,246 355 35,550
≥70  10,032,924 15 641,454 91 109,077
*The cost, 5-year survival, LYS and ICER values were all age-adjusted. All 
costs estimates were inflated to 2009 values. KW, Korean Won; LYS, life-years 
saved. a1,000 KW/survival, b1,000 KW/LYS
Figure 1. Sensitivity Analyses Results with 
Incremental Cost-effectiveness Ratios Regarding 
Life-years Saved in the Screened Group Compared 
to the Non-screened Group
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previously experienced false-positive mammograms 
were more likely to report symptoms of anxiety and 
depression (Jatoi et al., 2006). Due to the high rates of 
false-positive screening results in Korea, many women 
needlessly received further testing, which led to more 
expensive costs. Cost-effectiveness was estimated from 
a government expenditure perspective in this study. 
If out-of-pocket costs for women with false-positive 
screening results were considered, the incremental costs 
per LYS for the screening group would be greater from 
a societal perspective.
The higher false-positive rate in this study might be 
caused by physicians who had lower mammography 
reading skills when the NCSP was expanded to cover the 
entire population in 2002-2003. Another possible reason 
could be the substantially higher breast density of Asian 
women than White women (El-Bastawissi et al., 2001). 
In a previous study, about 68.8% of Korean women in 
their 40s were found to have dense breasts (Jeon et al., 
2011). Because dense breasts make mammograms more 
difficult to read, it might explain the higher false-positive 
rate in women aged 40-54 years in this study. 
In the sensitivity analyses as well as the base analysis, 
women the age group of 70 or older showed the highest 
ICER compared to the other age groups, and this was 
most likely caused by the small sample size in this age 
group (participation rate: 4.63% in 2002-2003). One 
way toward a more cost-effective NCSP for breast 
cancer might be to restrict the target population by 
setting an upper age limit. According to our sensitivity 
analyses, setting an age limit of 70 would produce the 
most cost-effective outcomes, but beyond 70 years the 
ICER increases. 
While women aged 40 years or over are the target 
population for the NCSP for breast cancer in Korea, 
Western countries, including the United States, Canada 
and the United Kingdom, recommend that women 
receive screening starting at age 50 years (Graham-
Rowe, 2012). Extending the screening age to women 
under 40 would not improve the cost-effectiveness of 
the screening program, as younger women are more 
likely to have denser breasts, which would increase 
the risk of false-positive screening results (Graham-
Rowe, 2012). However, considering that breast cancer 
has an earlier onset in Korean women, setting a lower 
age limit for breast cancer screening program might 
be a contradiction. Reducing false-positive screening 
results is the key for the NCSP to be cost-effective, and 
thus efforts to increase sensitivity, such as education 
for radiologists in reading mammograms, might be 
immediately needed. 
While this research has examined the cost-
effectiveness of breast cancer screening in Korea based 
on actual data rather than hypothetical estimates, there 
are several limitations in this study. First, while direct 
screening costs were identified in this study, medical 
costs for cancer treatment were not considered by cancer 
stage. Treatment costs for women with breast cancer 
would have been the same in the screened and non-
screened groups, but there were more early-stage cancers 
represented in screened group (Table 4). Therefore it is 
probable that the ICER including treatment costs would 
have been lower in the screening group. 
Second, while the ICER estimates were standardized 
by age, other various characteristics associated with 
screening participation, such as area of residence area 
and education level, were not adjusted for in this group. 
Previous studies have shown that people with lower 
socioeconomic status were less likely to participate in 
screening programs (Song and Fletcher, 1998; Bobo 
et al., 2004; 2006). Thus, different health behaviors 
according to different socioeconomic backgrounds might 
be related to the health outcomes of screening program, 
and these effects could not be examined in this study. 
Third, while quality-adjusted life years (QALYs) are 
usually considered as an integrated outcome measure, 
they were not considered in this study. Indeed, no study 
measuring QALY for Korean breast cancer patients has 
been found. Among previous studies conducted in other 
countries, only three used QALYs as an outcome measure 
for the cost-effectiveness of breast cancer screening 
(Stout et al., 2006; Schousboe et al., 2011; Wong et al., 
2012). Indeed, the results obtained with LYS and QALYs 
were similar (Carles et al., 2011). 
Finally, while our follow-up period was 5 years, 
a longer follow-up period might be needed to gain 
more stable and valid cost-effectiveness outcomes. 
For example, the cost-effectiveness of mammography 
screening for women aged 50-79 years in the United 
States was dominated when the observational period 
was 3 years (Wong et al., 2010). In contrast, it turned 
out to produce ICER of 34,000 USD/QALY when the 
observation period was lengthened to 11 years (Stout et 
al., 2006).
In conclusion, this study examined the cost-
effectiveness of the NCSP for breast cancer in 2002- 2003 
and showed an ICER per LYS of 42 million KW. This 
cost could be thought of as within the affordable range. 
However the high number of false-positive screening 
results might lead to an argument in the discussion about 
resource allocation for cancer in Korea. The present 
study serves as an important basis for interventions to 
improve the cost-effectiveness of breast cancer screening 
in Korea. 
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